According to Amphivena.com, Jeanmarie Guenot, PhD., serves as the president of Amphivena Therapeutics Inc. The company develops immune therapies for cancer treatment, and it is based in San Francisco. Having a lot of experience in business administration in the public and private sectors, she deals with project and alliance management, commercial development, pharmaceutical research and development (R&D), and venture capital. She has over two decades experience in biotechnology and the pharmaceutical industry.
Jeanmarie Guenot began her career in business at Atlas Venture. She managed various venture capital investments including life science startup companies. She kicked off her scientific career at Hoffmann La-Roche where she was the chief scientist in pre-clinical R&D.
Before her current role at Amphivena, Jeanmarie Guenot founded, developed and managed SKS Ocular. The startup was an ophthalmic company which specialized in dry AMD, a type of macular degeneration. The company steadily released ocular drug technologies and therapies for macular degeneration, ocular inflammation, and glaucoma.
She had also worked at Hoffmann-La Roche in Basel and Shanghai as a business consultant between 2008 and 2009. Dr. Guenot earlier served as the Vice President of Corporate and Business Development, PDL BioPharma. At the company, she led mergers and acquisitions, licensing, and alliance management for a spectrum of corporate products.
MarketWired reported that Jeanmarie initiated and negotiated the strategic collaboration between PDL and Biogen Idec which was a 50:50 co-commercialization and co-development deal. It involved three drug candidates for Phase II cancer and autoimmune disease.
This alliance was worth $800 million, and it included an equity investment of $100 million in PDL as well as a therapeutic candidate shared by Hoffmann La-Roche and Biogen Idec-PDL. Dr. Guenot has firsthand alliance management experience in cardiovascular disease, neurology, oncology, autoimmune diseases and ophthalmic ailments.
Under Jeanmarie’s leadership, Amphivena has made major breakthroughs in the development of cancer treatment drugs and therapies. A collection of antibodies developed by Amphivena which target CD33 and CD3 were assessed across rigorous systems in 2015 to determine their suitability for clinical treatment.
Leading researchers from the Washington University School of Medicine and the Fred Hutchinson Cancer Research Center observed that:
- The drugs inhibited the robust growth of tumors.
- The antibodies nearly eliminated leukemic cells from various compartments such as the spleen and the bone marrow.
Learn more about her important work through Takeda, a recent partner with Jeanmarie Guenot’s Amphivena Therapeutics.